Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02879695
Title Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

acute lymphoblastic leukemia

acute leukemia


Blinatumomab + Ipilimumab + Nivolumab

Age Groups: senior | adult | child
Covered Countries USA

Facility Status City State Zip Country Details
Yale University Recruiting New Haven Connecticut 06520 United States Details
University of Kentucky/Markey Cancer Center Recruiting Lexington Kentucky 40536 United States Details
Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore Maryland 21287 United States Details
Dana-Farber Cancer Institute Recruiting Boston Massachusetts 02215 United States Details
Ohio State University Comprehensive Cancer Center Recruiting Columbus Ohio 43210 United States Details
University of Pittsburgh Cancer Institute (UPCI) Active, not recruiting Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from for the field